ALVO vs. FATE, LXEO, ITOS, REPL, TCRX, ADPT, TRML, OCGN, TSHA, and EDIT
Should you be buying Alvotech stock or one of its competitors? The main competitors of Alvotech include Fate Therapeutics (FATE), Lexeo Therapeutics (LXEO), iTeos Therapeutics (ITOS), Replimune Group (REPL), TScan Therapeutics (TCRX), Adaptive Biotechnologies (ADPT), Tourmaline Bio (TRML), Ocugen (OCGN), Taysha Gene Therapies (TSHA), and Editas Medicine (EDIT). These companies are all part of the "biological products, except diagnostic" industry.
Alvotech (NYSE:ALVO) and Fate Therapeutics (NASDAQ:FATE) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, community ranking, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.
Alvotech has a beta of -0.02, suggesting that its stock price is 102% less volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 1.8, suggesting that its stock price is 80% more volatile than the S&P 500.
Fate Therapeutics has lower revenue, but higher earnings than Alvotech. Alvotech is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks.
Alvotech has a net margin of -967.97% compared to Fate Therapeutics' net margin of -2,933.79%. Alvotech's return on equity of 0.00% beat Fate Therapeutics' return on equity.
Alvotech presently has a consensus target price of $12.67, indicating a potential downside of 6.17%. Fate Therapeutics has a consensus target price of $6.58, indicating a potential upside of 59.02%. Given Fate Therapeutics' higher possible upside, analysts clearly believe Fate Therapeutics is more favorable than Alvotech.
Fate Therapeutics received 475 more outperform votes than Alvotech when rated by MarketBeat users. Likewise, 68.62% of users gave Fate Therapeutics an outperform vote while only 36.36% of users gave Alvotech an outperform vote.
In the previous week, Fate Therapeutics had 21 more articles in the media than Alvotech. MarketBeat recorded 25 mentions for Fate Therapeutics and 4 mentions for Alvotech. Alvotech's average media sentiment score of 0.00 beat Fate Therapeutics' score of -0.02 indicating that Alvotech is being referred to more favorably in the media.
97.5% of Fate Therapeutics shares are owned by institutional investors. 5.0% of Fate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Fate Therapeutics beats Alvotech on 12 of the 17 factors compared between the two stocks.
Get Alvotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alvotech Competitors List
Related Companies and Tools
